Colinz Laboratories has scheduled its 40th Annual General Meeting (AGM) for Tuesday, September 22, 2026, at 2:30 pm. The meeting will be conducted through Video Conferencing or Other Audio Visual Means (OAVM), with the company’s registered office in Mumbai deemed as the venue.

The primary business items include the adoption of the audited financial statements for the fiscal year ended March 31, 2026, and the reappointment of Mr. N. K. Menon as Whole-Time Director and Chief Executive Officer. Shareholders will also vote on the appointment of Mrs. Vijaya Mani as a Non-Executive, Non-Independent Director.

Key Agenda Items

The AGM notice outlines several ordinary and special resolutions for shareholder approval:

• Adoption of Financials: Consideration and adoption of the audited balance sheet, statement of profit and loss, and cash flow statement for FY26, along with the reports of the Board of Directors and Independent Auditors.
• Director Reappointment: Reappointment of Mr. N. K. Menon (DIN: 01111297), who retires by rotation. He will serve as Whole-Time Director and CEO for one year from October 1, 2026, to September 30, 2027.
• New Director Appointment: Appointment of Mrs. Vijaya Mani (DIN: 11363910) as a Director (Promoter, Non-Executive). She was initially appointed as an Additional Director on November 11, 2025.

Remuneration Details

Mr. N. K. Menon’s reappointment requires a special resolution due to his age exceeding 70 years. His remuneration package for the upcoming tenure is structured as follows:

The package includes statutory benefits such as gratuity, insurance premiums, and medical claims. House rent allowance is capped at 50% of the basic salary. Mr. Menon will not receive sitting fees for board or committee meetings.

Voting and Record Dates

The register of members and share transfer books will remain closed from September 15, 2026, to September 22, 2026, both days inclusive. The cut-off date for determining eligibility for remote e-voting is September 15, 2026.

Remote e-voting will be available from 9:00 am on September 19, 2026, to 5:00 pm on September 21, 2026. Members who have not voted remotely can cast their votes electronically during the AGM. Ms. Ashwini Vaze, Practising Company Secretary, has been appointed as the scrutinizer for the e-voting process.

The open offer initiated by Annjana Dugar, Likhitta Dugar, Antariksh Dugar, and Padam Dugar to acquire a 26% stake in Colinz Laboratories commenced on August 7, 2026. The acquirers are offering ₹54 per equity share to purchase up to 6,54,966 fully paid-up shares, representing a maximum consideration of ₹3,53,68,164. This mandatory offer follows the acquisition agreement dated June 18, 2026, which triggered the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Public shareholders must decide whether to tender their shares before the tendering period concludes on August 20, 2026.

The Committee of Independent Directors (IDC) recommended that shareholders accept the offer, deeming it fair and reasonable under Regulation 26(7) of the SEBI (SAST) Regulations, 2011. However, the IDC cautioned that the company’s equity shares trade on the Bombay Stock Exchange at prices higher than the ₹54 offer price. Shareholders were advised to evaluate the offer against prevailing market rates. Saffron Capital Advisors Private Limited serves as the manager to the open offer, while Bigshare Services Private Limited acts as the registrar.

Revised Timeline and Key Dates

The schedule of activities was revised following SEBI observations received on July 22, 2026. The identified date for determining eligible shareholders was July 24, 2026. Letters of offer were dispatched electronically on July 29, 2026, and via speed post on July 31, 2026. The last date for upward revision of the offer price or size was August 5, 2026. Payment of consideration or return of shares is scheduled for completion by September 4, 2026.

Financial Position and Strategic Intent

Colinz Laboratories reported a profit after tax of ₹51.45 lakh for FY26, compared to ₹49.66 lakh in FY25 and ₹48.67 lakh in FY24. The company’s net worth stood at ₹1,004.31 lakh as of March 31, 2026, with borrowings aggregating to ₹38.99 lakh. The acquirers view the transaction as a long-term strategic investment to consolidate control and enhance operational efficiencies in the pharmaceutical formulations business.

Contingent Liabilities and Disclosures

A certificate from M/s. Kirtane & Pandit LLP disclosed a contingent liability of ₹3.61 lakh for Colinz Laboratories as of March 31, 2026, related to Dividend Distribution Tax. The company filed a rectification application on June 2, 2026, under Section 154, and the matter remains pending. Conversely, the acquirers have nil contingent liabilities as certified by M/s. S. Satyaprakash & Co LLP. No competing offers exist, and the last date for such offers has expired.